CDK4/6 inhibitors may be a future treatment modality for glioma patients with pathogenic CDKN2A variants causing melanoma-astrocytoma syndrome [77] detected here in one CDKN2A GV carrier with an anaplastic astrocytoma and a melanoma. Here, CDKN2A is linked to melanoma.